Effects of nabumetone, celecoxib, and ibuprofen on blood pressure control in hypertensive patients on angiotensin converting enzyme inhibitors.
Nonsteroidal anti-inflammatory drugs interfere with certain antihypertensive therapies. In a double-blind study, 385 hypertensive patients stabilized on an angiotensin converting enzyme inhibitor were treated with nabumetone, celecoxib, ibuprofen, or placebo for 4 weeks. Ibuprofen caused significantly greater increases in systolic (P < .001) and diastolic (P < .01) blood pressures (BPs) compared to placebo, but not nabumetone or celecoxib. The proportion of patients with systolic BP increases of clinical concern at end point was significantly higher (P < .001) for the ibuprofen group (16.7%; 15 of 90), but not for the nabumetone group (5.5%; 5 of 91) or the celecoxib group (4.6%; 4 of 87) compared to the placebo group (1.1%; 1 of 91).
Palmer
Robert
R
SmithKline Beecham Pharmaceuticals, GlaxoSmithKline Pharmaceuticals, Collegeville, Pennsylvania 19426-0989, USA.
Weiss
Robert
R
Zusman
Randall M
RM
Haig
Ann
A
Flavin
Susan
S
MacDonald
Brian
B
D000328:Adult; D000368:Aged; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use*; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000494:pharmacology*; D001794:Blood Pressure / Q000187:drug effects*; D002074:Butanones / Q000494:pharmacology*; D000068579:Celecoxib; D005260:Female; D006801:Humans; D006973:Hypertension / Q000188:drug therapy* / Q000503:physiopathology*; D007052:Ibuprofen / Q000494:pharmacology*; D008297:Male; D008875:Middle Aged; D000077430:Nabumetone; D011720:Pyrazoles; D013449:Sulfonamides / Q000494:pharmacology*
D000806:Angiotensin-Converting Enzyme Inhibitors; D000894:Anti-Inflammatory Agents, Non-Steroidal; D002074:Butanones; D011720:Pyrazoles; D013449:Sulfonamides; D000068579:Celecoxib; D000077430:Nabumetone; D007052:Ibuprofen